UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2018-07, Vol.29 (7), p.1541-1547

2018

Volltextzugriff (PDF)

CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver

Journal of cellular physiology, 2011-09, Vol.226 (9), p.2438-2447

2011

Volltextzugriff (PDF)

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

Breast (Edinburgh), 2023-04, Vol.68, p.S81-S82

2023

Volltextzugriff (PDF)

Anti-Cancer Treatments in Elderly (≥75 Years Old) Patients: A Retrospective Analysis

Value in health, 2014-11, Vol.17 (7), p.A663-A663

2014

Volltextzugriff (PDF)

Rational design of combination therapies and blockage of acquired targeted drug resistance

European journal of cancer (1990), 2016-07, Vol.61, p.S132-S132

2016

Volltextzugriff (PDF)

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

European journal of cancer (1990), 2016-12, Vol.69, p.S7-S7

2016

Volltextzugriff (PDF)

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European journal of cancer (1990), 2012-11, Vol.48 (17), p.3140-3149

2012

Volltextzugriff (PDF)

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S263-S264

2015

Volltextzugriff (PDF)

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Annals of oncology, 2020-08, Vol.31 (8), p.1001-1010

2020

Volltextzugriff (PDF)

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

Annals of oncology, 2012-05, Vol.23 (5), p.1341-1347

2012

Volltextzugriff (PDF)

433 Recurrence Score (RS) and Treatment Decisions in Node-positive (N+), Estrogen Receptor-positive (ER+) Breast Cancer Patients in Israel

European journal of cancer (1990), 2012-03, Vol.48, p.S173-S173

2012

Volltextzugriff (PDF)

342 INVITED The Role of Opioids in Alleviating Cancer-Related Dyspnea

European journal of cancer (1990), 2011, Vol.47, p.S77-S77

2011

Volltextzugriff (PDF)

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

Journal of hepatology, 2012-04, Vol.56, p.S555-S555

2012

Volltextzugriff (PDF)

Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy

Human reproduction (Oxford), 2016-04, Vol.31 (4), p.750-762

2016

Volltextzugriff (PDF)

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

European journal of cancer (1990), 2011, Vol.47, p.S346-S346

2011

Volltextzugriff (PDF)

PCN278 - Anti-Cancer Treatments in Elderly (≥75 Years Old) Patients: A Retrospective Analysis

Value in health, 2014-11, Vol.17 (7), p.A663-A663

2014

Volltextzugriff (PDF)

924 CF102 INDUCES APOPTOSIS OF LIVER CANCER WHILE PREVENTING APOPTOSIS IN LIVER INFLAMMATION: A NEW APPROACH TO TREAT LIVER DISEASES

Journal of hepatology, 2010, Vol.52, p.S358-S359

2010

Volltextzugriff (PDF)

Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma

Bone (New York, N.Y.), 2011-01, Vol.48 (1), p.S18-S19

2011

Volltextzugriff (PDF)

1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study

Annals of oncology, 2024-09, Vol.35, p.S805-S806

2024

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1842-1842

2019

Volltextzugriff (PDF)

Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)

Annals of oncology, 2019-11, Vol.30, p.ix126

2019

Volltextzugriff (PDF)

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)

Annals of oncology, 2022-07, Vol.33 (7), p.720-727

2022

Volltextzugriff (PDF)

76TiP Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in metastatic lung cancer

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S84

2023

Volltextzugriff (PDF)

309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1

Annals of oncology, 2021-09, Vol.32, p.S498-S499

2021

Volltextzugriff (PDF)

990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

Annals of oncology, 2024-09, Vol.35, p.S675-S675

2024

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(52)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

Anti-Cancer Treatments in Elderly (≥75 Years Old) Patients: A Retrospective Analysis

Rational design of combination therapies and blockage of acquired targeted drug resistance

Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

433 Recurrence Score (RS) and Treatment Decisions in Node-positive (N+), Estrogen Receptor-positive (ER+) Breast Cancer Patients in Israel

342 INVITED The Role of Opioids in Alleviating Cancer-Related Dyspnea

1411 CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY

Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy

5053 POSTER Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data

PCN278 - Anti-Cancer Treatments in Elderly (≥75 Years Old) Patients: A Retrospective Analysis

924 CF102 INDUCES APOPTOSIS OF LIVER CANCER WHILE PREVENTING APOPTOSIS IN LIVER INFLAMMATION: A NEW APPROACH TO TREAT LIVER DISEASES

Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma

1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS)

76TiP Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in metastatic lung cancer

309P Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1

990O Final results from phase I, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors

Aktive Filter

Suchergebnisse filtern